Skip to main content
. 2022 Oct 19;23(20):12511. doi: 10.3390/ijms232012511

Figure 3.

Figure 3

Proportions of co-occurring mutations in EGFR-mutated primary pulmonary adenocarcinoma. (a) Early-stage ACA (stages I–IIIA). (b) Advanced-stage ACA (stages IIIB–IV).